In adults with newly diagnosed immune thrombocytopenia, dexamethasone plus glycyrrhizinate gave a higher 6-month overall response than dexamethasone alone (56.25% vs 31.25%; p=0.0231; 96 analysed), but not at day 14. No grade 3–5 adverse events occurred.
RCTn = 111
Wang et al. A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia